These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32358915)

  • 21. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
    Powers JP; Li S; Jaen JC; Liu J; Walker NP; Wang Z; Wesche H
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2842-5. PubMed ID: 16563752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK).
    Asquith CRM; Treiber DK; Zuercher WJ
    Bioorg Med Chem Lett; 2019 Jul; 29(14):1727-1731. PubMed ID: 31129055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.
    Heron NM; Anderson M; Blowers DP; Breed J; Eden JM; Green S; Hill GB; Johnson T; Jung FH; McMiken HH; Mortlock AA; Pannifer AD; Pauptit RA; Pink J; Roberts NJ; Rowsell S
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1320-3. PubMed ID: 16337122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.
    Wenglowsky S; Ren L; Grina J; Hansen JD; Laird ER; Moreno D; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Sturgis HL; Voegtli WC; Vigers G; Willis B; Mathieu S; Rudolph J
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1923-7. PubMed ID: 24675381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK).
    Asquith CRM; Bennett JM; Su L; Laitinen T; Elkins JM; Pickett JE; Wells CI; Li Z; Willson TM; Zuercher WJ
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31698822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and evaluation of 7-azaindole derivatives bearing benzocycloalkanone motifs as protein kinase inhibitors.
    Qhobosheane MA; Legoabe LJ; Josselin B; Bach S; Ruchaud S; Petzer JP; Beteck RM
    Bioorg Med Chem; 2020 Jun; 28(11):115468. PubMed ID: 32284225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines.
    Saul S; Pu SY; Zuercher WJ; Einav S; Asquith CRM
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127284. PubMed ID: 32631507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Back-Pocket Optimization of 2-Aminopyrimidine-Based Macrocycles Leads to Potent EPHA2/GAK Kinase Inhibitors.
    Gerninghaus J; Zhubi R; Krämer A; Karim M; Tran DHN; Joerger AC; Schreiber C; Berger LM; Berger BT; Ehret TAL; Elson L; Lenz C; Saxena K; Müller S; Einav S; Knapp S; Hanke T
    J Med Chem; 2024 Aug; 67(15):12534-12552. PubMed ID: 39028937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.
    Converso A; Hartingh T; Garbaccio RM; Tasber E; Rickert K; Fraley ME; Yan Y; Kreatsoulas C; Stirdivant S; Drakas B; Walsh ES; Hamilton K; Buser CA; Mao X; Abrams MT; Beck SC; Tao W; Lobell R; Sepp-Lorenzino L; Zugay-Murphy J; Sardana V; Munshi SK; Jezequel-Sur SM; Zuck PD; Hartman GD
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1240-4. PubMed ID: 19155174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.
    Han W; Ding Y; Xu Y; Pfister K; Zhu S; Warne B; Doyle M; Aikawa M; Amiri P; Appleton B; Stuart DD; Fanidi A; Shafer CM
    J Med Chem; 2016 Apr; 59(7):3034-45. PubMed ID: 27002243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triazolopyridazine LRRK2 kinase inhibitors.
    Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.
    Jordan AM; Begum H; Fairweather E; Fritzl S; Goldberg K; Hopkins GV; Hamilton NM; Lyons AJ; March HN; Newton R; Small HF; Vishwanath S; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2724-9. PubMed ID: 27086121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
    Tsou HR; MacEwan G; Birnberg G; Zhang N; Brooijmans N; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2259-63. PubMed ID: 20188551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
    Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
    Teo T; Yang Y; Yu M; Basnet SK; Gillam T; Hou J; Schmid RM; Kumarasiri M; Diab S; Albrecht H; Sykes MJ; Wang S
    Eur J Med Chem; 2015 Oct; 103():539-50. PubMed ID: 26408454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamical insights of Mnk2 kinase activation by phosphorylation to facilitate inhibitor discovery.
    Kumarasiri M; Teo T; Wang S
    Future Med Chem; 2015; 7(2):91-102. PubMed ID: 25685999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
    Tsou HR; MacEwan G; Birnberg G; Grosu G; Bursavich MG; Bard J; Brooijmans N; Toral-Barza L; Hollander I; Mansour TS; Ayral-Kaloustian S; Yu K
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2321-5. PubMed ID: 20188552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.
    Chaikuad A; Diharce J; Schröder M; Foucourt A; Leblond B; Casagrande AS; Désiré L; Bonnet P; Knapp S; Besson T
    J Med Chem; 2016 Nov; 59(22):10315-10321. PubMed ID: 27766861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.